Abstract
Monocytes are circulating leukocytes of innate immunity derived from the bone marrow that interact with endothelial cells under physiological or pathophysiological conditions to orchestrate inflammation, angiogenesis, or tissue remodeling. Monocytes are attracted by chemokines and specific receptors to precise areas in vessels or tissues and transdifferentiate into macrophages with tissue damage or infection. Adherent monocytes and infiltrated monocyte-derived macrophages locally release a myriad of cytokines, vasoactive agents, matrix metalloproteinases, and growth factors to induce vascular and tissue remodeling or for propagation of inflammatory responses. Infiltrated macrophages cooperate with tissue-resident macrophages during all the phases of tissue injury, repair, and regeneration. Substances released by infiltrated and resident macrophages serve not only to coordinate vessel and tissue growth but cellular interactions as well by attracting more circulating monocytes (e.g. MCP-1) and stimulating nearby endothelial cells (e.g. TNF-α) to expose monocyte adhesion molecules. Prolonged tissue accumulation and activation of infiltrated monocytes may result in alterations in extracellular matrix turnover, tissue functions, and vascular leakage. In this review, we highlight the link between interactions of infiltrating monocytes and endothelial cells to regulate vascular and tissue remodeling with a special focus on how these interactions contribute to pathophysiological conditions such as cardiovascular and chronic liver diseases.
Introduction
Monocytes are not just passive immune responders; they are the "architects" of tissue remodeling that actively communicate with the vascular lining to build or repair organs. This review synthesizes how these cellular interactions dictate the balance between healthy regeneration and chronic diseases like atherosclerosis, liver cirrhosis, and cancer.
While we have long understood that monocytes migrate to sites of infection, their role as structural regulators is far more complex. The "handshake" between a circulating monocyte and the endothelial cells (ECs) lining our blood vessels is a high-stakes molecular negotiation. If this interaction goes right, tissues heal and new blood vessels grow (angiogenesis). If it goes wrong, it fuels the buildup of arterial plaques or the scarring of the liver.
The Mechanics of Monocyte Recruitment
The interaction between monocytes and the endothelium occurs in a highly regulated, multi-step process. This review synthesizes findings from 240 peer-reviewed studies to create a comprehensive model of these interactions, categorized into four distinct mechanical stages:
- Tethering and Rolling: Mediated by selectins, which act as the "Velcro" of the cell world.
- Activation: Triggered by chemokines (chemical beacons) binding to G-protein-coupled receptors.
- Firm Adhesion: Driven by integrins, molecular anchors like LFA-1 and VLA-4.
- Transmigration: The process of "crawling" between endothelial cells into the tissue, regulated by Junctional Adhesion Molecules (JAMs).
Key Insights into Tissue Remodeling
The paper moves past the simplistic "M1 (bad/inflammatory) vs. M2 (good/healing)" binary, highlighting that macrophages exist on a spectrum dictated by the local microenvironment of the vessel wall.
- The "Chaperone" Effect: One of the most striking insights is that monocyte-derived macrophages (MDMs) act as physical chaperones for new blood vessels. During angiogenesis, they help "bridge" the gaps between sprouting vessel tips, essentially acting as a biological construction crew.
- The Liver’s Double-Edged Sword: In the liver, recruited monocytes are essential for regeneration after surgery (like a partial hepatectomy). However, in chronic disease, these same cells are "hijacked" to drive fibrosis (scarring) and even help tumors build their own blood supply.
- Nanomedicine as a "Switch": The authors highlight a shift toward using nanoparticles to deliver siRNA or specific ligands directly to macrophages. This allows researchers to "flip the switch" on a cell's behavior—for example, reducing lipid uptake in arterial walls—without affecting other immune functions.
Clinical Implications and Results
The review provides a detailed "parts list" for vascular remodeling, identifying CCL2 (MCP-1) and CX3CL1 (Fractalkine) as the primary "GPS coordinates" that bring monocytes to damaged vessels.
In cardiovascular health, the paper notes that M1-like macrophages characterize "progression lesions" (unstable plaques), while M2-like cells are enriched in regressing, stable plaques. Furthermore, the review details how tumors secrete VEGF and Ang-2 to recruit monocytes, which then "re-educate" the local environment to suppress the body's natural anti-cancer T-cell response.
Limitations and Future Directions
The primary limitation identified is cellular heterogeneity. Even with our current knowledge, we struggle to distinguish between "resident" macrophages (born in the tissue) and "recruited" macrophages (arriving from the blood) once a disease is underway.
The authors suggest that the future of the field lies in Single-Cell RNA Sequencing (scRNA-seq). By mapping the gene expression of individual cells during the exact moment they cross the vascular barrier, researchers hope to identify "checkpoint" molecules. Targeting these checkpoints could allow us to stop the "bad" recruitment seen in heart disease while preserving the "good" recruitment needed for wound healing.
Summary updated